Biosensor Device Uses CRISPR-Cas9 to Detect Target DNA Sequence
|
By LabMedica International staff writers Posted on 01 Apr 2019 |

Image: A close-up of the CRISPR-Chip device (Photo courtesy of Keck Graduate Institute).
A team of biomedical engineers has developed and tested a graphene-based biosensor device that uses CRISPR/Cas9 technology to enable the digital detection of a target DNA sequence within intact genomic material.
CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system from Streptococcus pyogenes is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.
In contrast to classical methods for the detection of nucleic acids, which require many reagents and expensive and bulky instrumentation, the "CRISPR-Chip" device developed by investigators at the University of California, Berkeley (USA) and the Keck Graduate Institute (Claremont, CA, USA) exploited the gene-targeting capacity of catalytically deactivated CRISPR-associated protein 9 (Cas9) complexed with a specific single-guide RNA and immobilized on a graphene-based field-effect transistor. This created a label-free nucleic-acid-testing device whose output signal could be measured with a simple handheld reader.
Mechanistically, the CRISPR complex located the target DNA site on the genome, bound to it, and triggered a change in the electrical conductance of the graphene, which, in turn, changed the electrical characteristics of the transistor. These changes were detected with a hand-held device.
The investigators used CRISPR–Chip to analyze DNA samples collected from HEK293T cell lines expressing blue fluorescent protein, and clinical samples of DNA with two distinct mutations at exons commonly deleted in individuals with Duchenne muscular dystrophy. In the presence of genomic DNA containing the target gene, CRISPR–Chip generated, within 15 minutes and without the need for amplification, a significant enhancement in output signal relative to samples lacking the target sequence.
"We have developed the first transistor that uses CRISPR to search your genome for potential mutations," said senior author Dr. Kiana Aran, assistant professor of medical diagnostics and therapeutics at the Keck Graduate Institute. "You just put your purified DNA sample on the chip, allow CRISPR to do the search and the graphene transistor reports the result of this search in minutes. Graphene's super-sensitivity enabled us to detect the DNA searching activities of CRISPR. CRISPR brought the selectivity, graphene transistors brought the sensitivity and, together, we were able to do this PCR-free or amplification-free detection. Combining modern nanoelectronics with modern biology opens a new door to get access to new biological information that was not accessible before."
The CRISP-Chip device was described in the March 25, 2019, online edition of the journal Nature Biomedical Engineering.
Related Links:
University of California, Berkeley
Keck Graduate Institute
CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system from Streptococcus pyogenes is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.
In contrast to classical methods for the detection of nucleic acids, which require many reagents and expensive and bulky instrumentation, the "CRISPR-Chip" device developed by investigators at the University of California, Berkeley (USA) and the Keck Graduate Institute (Claremont, CA, USA) exploited the gene-targeting capacity of catalytically deactivated CRISPR-associated protein 9 (Cas9) complexed with a specific single-guide RNA and immobilized on a graphene-based field-effect transistor. This created a label-free nucleic-acid-testing device whose output signal could be measured with a simple handheld reader.
Mechanistically, the CRISPR complex located the target DNA site on the genome, bound to it, and triggered a change in the electrical conductance of the graphene, which, in turn, changed the electrical characteristics of the transistor. These changes were detected with a hand-held device.
The investigators used CRISPR–Chip to analyze DNA samples collected from HEK293T cell lines expressing blue fluorescent protein, and clinical samples of DNA with two distinct mutations at exons commonly deleted in individuals with Duchenne muscular dystrophy. In the presence of genomic DNA containing the target gene, CRISPR–Chip generated, within 15 minutes and without the need for amplification, a significant enhancement in output signal relative to samples lacking the target sequence.
"We have developed the first transistor that uses CRISPR to search your genome for potential mutations," said senior author Dr. Kiana Aran, assistant professor of medical diagnostics and therapeutics at the Keck Graduate Institute. "You just put your purified DNA sample on the chip, allow CRISPR to do the search and the graphene transistor reports the result of this search in minutes. Graphene's super-sensitivity enabled us to detect the DNA searching activities of CRISPR. CRISPR brought the selectivity, graphene transistors brought the sensitivity and, together, we were able to do this PCR-free or amplification-free detection. Combining modern nanoelectronics with modern biology opens a new door to get access to new biological information that was not accessible before."
The CRISP-Chip device was described in the March 25, 2019, online edition of the journal Nature Biomedical Engineering.
Related Links:
University of California, Berkeley
Keck Graduate Institute
Latest Technology News
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
- AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
- AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
- AI Model Achieves Breakthrough Accuracy in Ovarian Cancer Detection
- Portable Biosensor Diagnoses Psychiatric Disorders Using Saliva Samples
- Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement

- Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
- Viral Biosensor Test Simultaneously Detects Hepatitis and HIV
- Acoustofluidic Device to Transform Point-Of-Care sEV-Based Diagnostics
- AI Algorithm Assesses Progressive Decline in Kidney Function
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read moreRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read moreAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








